CAJ | 학술논문

目的：探讨新疆地区乳腺浸润性导管癌不同分子亚型的分布，并研究分子亚型与各临床病理学特征的关系。方法收集2013年1月—2014年1月明确诊断为乳腺浸润性导管癌病例621例，根据雌激素受体（ ER）、孕激素受体（ PR）、表皮生长因子受体－2（ HER－2）和Ki－67的表达情况，把所有病例划分为Luminal A型、Luminal B型、HER－2过表达型及Basal－like型，然后结合临床病理特征进行比较统计。结果621例中Luminal B型占53．1％，Luminal A型、HER－2过表达型和Basal－like型分别占14．5％、15．9％、16．4％。各分子亚型与肿瘤大小、病理组织学分级、肿瘤病理分期、ER状态、PR状态、HER－2状态均有关（P＜0．05），与年龄、淋巴结状态无关（P＞0．05）。结论浸润性导管癌患者各分子亚型与其临床病理学特征有密切关系，分子分型有利于指导临床个体化治疗方案的制定。
목적：탐토신강지구유선침윤성도관암불동분자아형적분포，병연구분자아형여각림상병이학특정적관계。방법수집2013년1월—2014년1월명학진단위유선침윤성도관암병례621례，근거자격소수체（ ER）、잉격소수체（ PR）、표피생장인자수체－2（ HER－2）화Ki－67적표체정황，파소유병례화분위Luminal A형、Luminal B형、HER－2과표체형급Basal－like형，연후결합림상병리특정진행비교통계。결과621례중Luminal B형점53．1％，Luminal A형、HER－2과표체형화Basal－like형분별점14．5％、15．9％、16．4％。각분자아형여종류대소、병리조직학분급、종류병리분기、ER상태、PR상태、HER－2상태균유관（P＜0．05），여년령、림파결상태무관（P＞0．05）。결론침윤성도관암환자각분자아형여기림상병이학특정유밀절관계，분자분형유리우지도림상개체화치료방안적제정。
Objective To investigate the distribution of breast invasive ductal carcinoma with different molecular subtypes ,and to study the relationship between molecular subtypes and clinical pathological features in Xinjiang area .Methods A total of 621 patients with IDC from January 2013 to January 2014 was classified into Luminal A type,Luminal B type,HER-2 overexpression type and Basal -like type,different molecular subtypes according to the estrogen receptor(ER),progesterone receptor(PR),epidermal growth factor receptor -2(HER-2) and Ki-67,and compared the statistics combining with the clinical pathological characteristics of IDC .Re-sults The result showed that Luminal B type accounted for 53.1%,Luminal A type,HER-2 overexpression type and Basal-like type accounted for 14.5%,15.9%,16.4%,respectively.There were significant differences between the molecular subtypes and tumor size ,histological grade ,tumor pathological stage ,the expression of ER , PR and HER-2(P<0.05 for all).There were no correlations between the molecular subtypes and age ,as well as lymph node metastasis(P>0.05).Conclusion There is a close relationship between invasive ductal carcino-ma of different molecular subtypes and clinical pathological characteristics .The molecular subtypes are beneficial to treatment guidelines for clinical individual .